-transparent.png){kind=logo}
A six-month, multicenter, double-blind study compared the efficacy and safety of two therapeutic regimens in 332 patients with osteoarthritis. The patients received either 1,000 mg of nabumetone as a single bedtime dose or 900 mg of aspirin in four divided doses. At the end of the study, patients in both treatment groups showed significant improvement from baseline for all five parameters; no statistically or clinically significant differences were observed between the groups. The safety data did reveal clinically and statistically significant differences between the groups. Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent). The results of this study demonstrated that nabumetone, 1,000 mg at bedtime, is as efficacious as aspirin, 900 mg four times daily, produces fewer adverse effects, and is indicated in the treatment of osteoarthritis.
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
January 1984,
International journal of tissue reactions,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
October 1987,
The American journal of medicine,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
April 2000,
Alimentary pharmacology & therapeutics,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
January 1995,
Clinical therapeutics,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
November 1992,
The Journal of rheumatology. Supplement,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
December 2001,
International journal of clinical pharmacology and therapeutics,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
June 1997,
Medicina clinica,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
May 2001,
Zhonghua yi xue za zhi,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
January 1995,
Clinical therapeutics,
D J Appelrouth, and
S Baim, and
R W Chang, and
M H Cohen, and
D W Englund, and
B F Germain, and
S S Hartman, and
A Jaffer, and
B J Mullen, and
F E Smith
February 1979,
Rheumatology and rehabilitation,
